Perfluorooctyl bromide (PFOB) has been clinically studied as a respiratory medium for liquid ventilation. This respiratory support technique employs PFOB as a vehicle for the transport of oxygen to the lung. PFOB is also envisioned as a pulmonary drug delivery vehicle that allows (a) direct delivery of a drug to the lung in high concentrations at the injured lung parenchyma, (b) equal distribution within the lung, and (c) limited systemic distribution (which reduces systemic toxicity). Unfortunately, typical drug molecules are insoluble in PFOB, which currently limits its usefulness as drug delivery vehicle. To overcome the solubility problem, we have synthesized a series of model prodrugs of nicotinic acids. These prodrugs show a high solubility in PFOB and are also water soluble, readily hydrolyzed in the presence of esterases and show little cytotoxicity. Our working hypothesis is that, because of these properties, prodrugs, for example prodrugs of nicotinic acid, can be successfully delivered to the lung where they will partition into the lung tissue, thus achieving higher tissue levels compared to conventional drug delivery approaches. The parent drug will be released by chemical or enzymatic degradation within the tissue. Herein we propose to (i) investigate and model the partition behavior of nicotinic acid prodrugs relevant to cellular uptake using a linear free energy relationship (LFER), (ii) study the transport of nicotinic acid prodrugs in a cell culture model of the perfluorocarbon (PFOB)-tissue interface, and (iii) evaluate the drug delivery system in vivo by investigating the uptake and distribution of C-14 labeled prodrugs after administration with PFOB in male rats. This proposal brings together a multidisciplinary research team of chemists, cell/molecular biologists and chemical engineers. Our approach of employing a linear free energy relationship (LFER) to assess the partition behavior at the PFOB tissue interface in combination with cell culture and animal studies will allow us to better understand and predict the parameters relevant for the release of drugs from a PFOB-based drug formulation. These findings will allow us to design (pro-)drugs suitable for pulmonary administration using PFOB as vehicle, thus providing a novel and superior method for the targeted administration of drugs to the injured sites of the lung.

National Institute of Health (NIH)
National Institute of Biomedical Imaging and Bioengineering (NIBIB)
Exploratory/Developmental Grants (R21)
Project #
Application #
Study Section
Special Emphasis Panel (ZRG1-SSS-M (56))
Program Officer
Moy, Peter
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
University of Iowa
Public Health & Prev Medicine
Schools of Public Health
Iowa City
United States
Zip Code
Ojogun, Vivian; Knutson, Barbara L; Vyas, Sandhya et al. (2010) Fluorophilicity of Alkyl and Polyfluoroalkyl 1 Nicotinic Acid Ester Prodrugs. J Fluor Chem 131:784-790
Ojogun, Vivian; Vyas, Sandhya M; Lehmler, Hans-Joachim et al. (2010) Partitioning of homologous nicotinic acid ester prodrugs (nicotinates) into dipalmitoylphosphatidylcholine (DPPC) membrane bilayers. Colloids Surf B Biointerfaces 78:75-84
Li, Xueshu; Turánek, Jaroslav; Knötigová, Pavlína et al. (2009) Hydrophobic tail length, degree of fluorination and headgroup stereochemistry are determinants of the biocompatibility of (fluorinated) carbohydrate surfactants. Colloids Surf B Biointerfaces 73:65-74
Lehmler, Hans-Joachim; Xu, Ling; Vyas, Sandhya M et al. (2008) Synthesis, physicochemical properties and in vitro cytotoxicity of nicotinic acid ester prodrugs intended for pulmonary delivery using perfluorooctyl bromide as vehicle. Int J Pharm 353:35-44
Vyas, Sandhya M; Kania-Korwel, Izabela; Lehmler, Hans-Joachim (2007) Differences in the isomer composition of perfluoroctanesulfonyl (PFOS) derivatives. J Environ Sci Health A Tox Hazard Subst Environ Eng 42:249-55
Xie, W; Kania-Korwel, I; Bummer, P M et al. (2007) Effect of potassium perfluorooctanesulfonate, perfluorooctanoate and octanesulfonate on the phase transition of dipalmitoylphosphatidylcholine (DPPC) bilayers. Biochim Biophys Acta 1768:1299-308
Lehmler, Hans-Joachim (2007) Perfluorocarbon compounds as vehicles for pulmonary drug delivery. Expert Opin Drug Deliv 4:247-62
Lehmler, Hans-Joachim; Bummer, Paul M (2005) Mixing behavior of 10-(perfluorohexyl)-decanol and DPPC. Colloids Surf B Biointerfaces 44:74-81
Lehmler, Hans-Joachim; Fortis-Santiago, Azarih; Nauduri, Dhananjaya et al. (2005) Interaction of long-chain nicotinates with dipalmitoylphosphatidylcholine. J Lipid Res 46:535-46
Lehmler, Hans-Joachim; Bummer, Paul M (2005) Interaction of a partially fluorinated long-chain nicotinate with dipalmitoylphosphatidylcholine. J Lipid Res 46:2415-22

Showing the most recent 10 out of 11 publications